Amf Tjanstepension Ab Vertex Pharmaceuticals Inc Transaction History

Amf Tjanstepension Ab

$13.5 Billion
Q3 2024

A detailed history of Amf Tjanstepension Ab transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Amf Tjanstepension Ab holds 167,918 shares of VRTX stock, worth $84.4 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares

167,918

Previous 167,918 -0.0%

Holding current value

$84.4 Million

Previous $78.1 Million -0.0%

% of portfolio

0.58%

Previous 0.58%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 03, 2024	SELL	$460.0 - $505.78 $176 Million - $193 Million	-381,782 Reduced 69.45%	167,918 $78.1 Million
Q2 2024 Jul 10, 2024	BUY	$392.81 - $485.53 $216 Million - $267 Million	549,700 New	549,700 $258 Million
Q3 2023 Oct 26, 2023	SELL	$338.18 - $362.46 $11.4 Million - $12.3 Million	-33,839 Reduced 64.18%	18,890 $6.57 Million
Q2 2023 Jul 05, 2023	SELL	$314.42 - $351.91 $22.1 Million - $24.7 Million	-70,242 Reduced 57.12%	52,729 $18.6 Million
Q1 2023 Apr 24, 2023	SELL	$283.23 - $323.1 $171,070 - $195,152	-604 Reduced 0.49%	122,971 $38.7 Million
Q4 2022 Jan 26, 2023	BUY	$285.76 - $321.48 $9.97 Million - $11.2 Million	34,879 Added 39.32%	123,575 $0
Q3 2022 Oct 26, 2022	SELL	$273.83 - $305.53 $1.05 Million - $1.17 Million	-3,842 Reduced 4.15%	88,696 $25.7 Million
Q2 2022 Jul 26, 2022	SELL	$234.96 - $292.55 $7.58 Million - $9.44 Million	-32,259 Reduced 25.85%	92,538 $26.1 Million
Q1 2022 May 05, 2022	SELL	$221.42 - $260.97 $247,990 - $292,286	-1,120 Reduced 0.89%	124,797 $32.6 Million
Q4 2021 Feb 08, 2022	SELL	$177.01 - $223.45 $2.93 Million - $3.69 Million	-16,532 Reduced 11.61%	125,917 $27.7 Million
Q3 2021 Nov 03, 2021	SELL	$181.39 - $202.99 $2.36 Million - $2.65 Million	-13,034 Reduced 8.38%	142,449 $25.8 Million
Q2 2021 Aug 11, 2021	SELL	$187.49 - $221.1 $3.18 Million - $3.75 Million	-16,953 Reduced 9.83%	155,483 $31.4 Million
Q1 2021 Apr 28, 2021	SELL	$207.02 - $241.31 $165,616 - $193,048	-800 Reduced 0.46%	172,436 $37.1 Million
Q4 2020 Feb 02, 2021	SELL	$207.01 - $276.09 $41.7 Million - $55.6 Million	-201,538 Reduced 53.78%	173,236 $40.9 Million
Q3 2020 Nov 09, 2020	BUY	$255.65 - $303.1 $8.45 Million - $10 Million	33,058 Added 9.67%	374,774 $102 Million
Q2 2020 Aug 13, 2020	BUY	$225.48 - $295.8 $2.4 Million - $3.14 Million	10,631 Added 3.21%	341,716 $99.2 Million
Q1 2020 Apr 14, 2020	BUY	$199.77 - $247.81 $31.4 Million - $38.9 Million	157,054 Added 90.24%	331,085 $78.8 Million
Q4 2019 Feb 12, 2020	BUY	$166.71 - $223.91 $1.12 Million - $1.51 Million	6,744 Added 4.03%	174,031 $38.1 Million
Q3 2019 Oct 29, 2019	SELL	$166.23 - $187.09 $64 Million - $72 Million	-385,014 Reduced 69.71%	167,287 $28.3 Million
Q2 2019 Jul 11, 2019	SELL	$164.61 - $190.37 $28.8 Million - $33.3 Million	-174,881 Reduced 24.05%	552,301 $101 Million
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $47.6 Million - $56.6 Million	290,570 Added 66.55%	727,182 $134 Million
Q4 2018 Jan 30, 2019	BUY	$151.91 - $192.21 $2.38 Million - $3.02 Million	15,699 Added 3.73%	436,612 $72.4 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $21.7 Million - $25 Million	129,587 Added 44.48%	420,913 $81.1 Million
Q2 2018 Aug 13, 2018	SELL	$145.72 - $169.96 $3.07 Million - $3.58 Million	-21,047 Reduced 6.74%	291,326 $49.5 Million
Q1 2018 May 10, 2018	SELL	$151.6 - $177.13 $1.18 Million - $1.38 Million	-7,776 Reduced 2.43%	312,373 $50.9 Million
Q4 2017 Feb 13, 2018	BUY	$137.28 - $155.55 $1.9 Million - $2.15 Million	13,819 Added 4.51%	320,149 $48 Million
Q3 2017 Nov 08, 2017	BUY	$148.13 - $162.24 $45.4 Million - $49.7 Million	306,330	306,330 $46.6 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amf Tjanstepension Ab, based on Form 13F filings with the SEC.

News

Stay updated on Amf Tjanstepension Ab with notifications on news.

Account

Amf Tjanstepension Ab Vertex Pharmaceuticals Inc Transaction History